Nektar Therapeutics Increase (Decrease) in Restricted Cash
Nektar Therapeutics (NKTR) reported Increase (Decrease) in Restricted Cash of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2018-03-01
- Nektar Therapeutics increase (decrease) in restricted cash for the quarter ending 2016-12-31 was $0.00.
- Nektar Therapeutics increase (decrease) in restricted cash for the quarter ending 2015-12-31 was $0.00.
- Nektar Therapeutics increase (decrease) in restricted cash for the quarter ending 2014-12-31 was $0.00.
- Nektar Therapeutics increase (decrease) in restricted cash for the quarter ending 2012-12-31 was $0.00.
- Nektar Therapeutics increase (decrease) in restricted cash for fiscal 2017 was $0.00.
- Nektar Therapeutics increase (decrease) in restricted cash for fiscal 2016 was $0.00.
- Nektar Therapeutics increase (decrease) in restricted cash for fiscal 2015 was -$25.00M.
- Nektar Therapeutics increase (decrease) in restricted cash for fiscal 2014 was $0.00.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 9 month as first filed | Increase (Decrease) in Restricted Cash 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-01 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $0.00 10-K · filed 2018-03-01 | ||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-04 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$25.00M 10-K · filed 2018-03-01 | ||
| 2015-09-30 | -$25.00M 10-Q · filed 2016-11-04 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $0.00 10-K · filed 2017-03-01 | ||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-06 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $25.00M 10-K · filed 2015-02-26 | ||
| 2012-09-30 | $25.00M 10-Q · filed 2013-11-07 | -$25.00M 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |